Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $40.0052W HIGH $99.50
Volume
130.44 K
Value Traded
24.05 M
Short % Float
25.6%
-2.46%Week
-17.76%1 Month
-17.84%3 Month
-5.12%6 Month
-38.36%5 Year
-34.81%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.42 B
EPS (TTM)
-6.40
P/E Ratio
-
Ent. Value
1.76 B
Total Shares
38.40 M
Float Shares
28.15 M
Insiders
26.67%
Institutions
94.99%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IRON Catalyst Timeline
Dated clinical, regulatory and corporate events for Disc Medicine, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Disc Medicine, Inc.
295Total events
24Upcoming
64Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationDISC-3405Presentation
RESTORE-PV Phase 2 data to be featured in oral presentation at SOHO
Polycythemia Vera (PV)source ↗
▲Poster PresentationDISC-3405Presentation
Initial RESTORE-PV Phase 2 results presented in poster session at 2026 SOHO Annual Meeting
Polycythemia Vera (PV)source ↗
●Poster PresentationPresentation
New systematic literature review characterizing humanistic burden of anemia in MF presented at SOHO
anemia of myelofibrosis (MF)source ↗
▲Poster PresentationDISC-0974Presentation
Encore of positive RALLY-MF Phase 2 results in anemia of MF presented at SOHO
anemia of myelofibrosis (MF)source ↗
▲Type A MeetingbitopertinFiledFDA Meeting
Completed Type A meeting with FDA on bitopertin CRL
erythropoietic protoporphyria (EPP)source ↗
▲Product LaunchbitopertinFiledPost-Market
Launched Expanded Access Program (EAP) for bitopertin
erythropoietic protoporphyria (EPP)source ↗
▲EU Orphan DesignationDISC-0974Ex-US Regulatory
Received EU Orphan Drug Designation for selcodebart
myelofibrosissource ↗
▲Orphan Drug DesignationDISC-0974Designation
Received EU Orphan Drug Designation for selcodebart
myelofibrosissource ↗
◆Topline ReadoutDISC-3405Clinical Data
Initial data from RESTORE-PV expected in Q3 2026
polycythemia vera (PV)source ↗
▲Poster PresentationbitopertinFiledPresentation
Poster presentation of updated HELIOS data at EHA 2026
erythropoietic protoporphyriasource ↗
▲Oral PresentationDISC-0974Presentation
Oral presentation of updated RALLY-MF data at EHA 2026
myelofibrosis with anemiasource ↗
▲Type A MeetingbitopertinFiledFDA Meeting
Completed Type A meeting with FDA to discuss CRL for bitopertin NDA
erythropoietic protoporphyriasource ↗
◆Oral PresentationDISC-0974Presentation
Oral presentation of RALLY-MF Phase 2 data at ASCO 2026
anemia of myelofibrosissource ↗
▲Trial InitiationbitopertinFiledTrial
Phase 3 APOLLO trial ongoing
erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)source ↗
◆Oral PresentationDISC-0974Presentation
Updated Phase 2 data of DISC-0974 in MF anemia to be presented at ASCO
anemia of myelofibrosis (MF)source ↗
▲Oral PresentationbitopertinFiledPresentation
Presented updated HELIOS data at EHA Annual Meeting
erythropoietic protoporphyria (EPP)source ↗
▲Oral PresentationDISC-0974Presentation
Presented updated data from RALLY-MF at ASCO and EHA
anemia of myelofibrosissource ↗
◆AbstractDISC-0974Presentation
Abstract publication on ASCO conference website
anemia of myelofibrosissource ↗
▲Enrollment CompletebitopertinFiledTrial
Completed enrollment of Phase 3 APOLLO study of bitopertin in EPP
erythropoietic protoporphyria (EPP)source ↗
◆Timing GuidancebitopertinFiledPresentation
PDUFA date expected (if Priority Review granted, ~6 months after filing acceptance)
erythropoietic protoporphyria (EPP)source ↗
◆Type A MeetingbitopertinFiledFDA Meeting
Type A meeting with FDA to review approach for CRL resubmission
erythropoietic protoporphyria (EPP)source ↗
▲Enrollment CompletebitopertinFiledTrial
Last participant randomized and dosed in Phase 3 APOLLO trial
erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)source ↗
◆Oral PresentationPresentation
Disc Medicine management to present at Barclays 28th Annual Global Healthcare Conference
◆Oral PresentationPresentation
Disc Medicine management to present at Jefferies Biotech on the Beach Summit
▲Enrollment CompletebitopertinFiledTrial
APOLLO enrollment completed
erythropoietic protoporphyria (EPP)source ↗
▼Complete Response LetterbitopertinFiledFDA Decision
FDA issued Complete Response Letter for bitopertin NDA for EPP
erythropoietic protoporphyria (EPP)source ↗
◆Oral PresentationPresentation
Corporate presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Type A MeetingbitopertinFiledFDA Meeting
Type A meeting with FDA confirmed APOLLO can serve as basis for CRL response
erythropoietic protoporphyriasource ↗
◆Timing GuidancebitopertinFiledPresentation
Anticipated FDA action date for bitopertin by end of January 2026
erythropoietic protoporphyriasource ↗
◆Product LaunchbitopertinFiledPost-Market
Potential US launch of bitopertin by end of January 2026, if approved
erythropoietic protoporphyriasource ↗
◆Oral PresentationPresentation
Further details on bitopertin commercialization and launch planning to be shared at JP Morgan Healthcare Conference in January 2026
◆Topline ReadoutDISC-0974Clinical Data
Initial data from Phase 2 RALLY-MF trial of DISC-0974 in anemia of MF
anemia of myelofibrosissource ↗
●Trial InitiationDISC-3405Trial
Initiate Phase 1b trial of DISC-3405 in sickle cell disease
sickle cell diseasesource ↗
◆Oral PresentationPresentation
Management call during ASH meeting to review highlights of presented data and plans for next steps
▲Interim AnalysisDISC-0974Trial
Interim results from RALLY-MF study of DISC-0974 in anemia of MF presented at ASH 2025
anemia of myelofibrosissource ↗
▲Oral PresentationDISC-0974Presentation
Positive initial data from RALLY-MF Phase 2 trial presented at ASH 2025
myelofibrosis with anemiasource ↗
◆Poster PresentationDISC-3405Presentation
Poster presentation on design of ongoing Phase 2 trial of DISC-3405 in polycythemia vera at ASH 2025
polycythemia verasource ↗
◆Poster PresentationDISC-0974Presentation
Poster presentation of initial data from RALLY-MF Phase 2 trial of DISC-0974 in anemia of myelofibrosis at ASH 2025
myelofibrosis and anemiasource ↗
◆Oral PresentationPresentation
Participation in Piper Sandler 37th Annual Healthcare Conference
◆Topline ReadoutDISC-0974Clinical Data
Initial data from Phase 2 RALLY-MF trial of DISC-0974 in anemia of MF
anemia of myelofibrosissource ↗
●Trial InitiationDISC-3405Trial
Initiate Phase 1b trial of DISC-3405 in sickle cell disease
sickle cell diseasesource ↗
▲FDA Filing AcceptedbitopertinFiledRegulatory Filing
NDA for bitopertin accepted by FDA on November 28, 2025
erythropoietic protoporphyriasource ↗
Past FDA Catalysts and PDUFA Decisions
How IRON actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-10 | DISC-3405 | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C55 / 100
Pipeline Score
$1.1B
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.5x
rNPV / MCap
Top 11%
Small Cap(rank 73 of 658)
Percentile Rank
Disc Medicine, Inc. carries a moderate pipeline score (55/100), with $1.8B risk-adjusted pipeline value, led by DISC-0974 in Inflammatory Bowel Disease (IBD) (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DISC-0974 Small moleculeNCT07368972 | Inflammatory Bowel Disease (IBD) | Phase 2 | RECRUITING | 21 | Mar 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every IRON program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Quisel John DDirector, Officer (Chief Executive Officer) | Option | 36,000 262,064 held | $1.01 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IRON
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 1.6 % (-5.9 %) | 179.21 M | 2.45 M |
IRON Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IRON ranks across every disease it competes in
Competitive Position is a premium feature
See how IRON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIRON News
IRONDisc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
Disc Medicine presented initial results from the RESTORE-PV Phase 2 trial for DISC-3405, showing promising outcomes in patients with polycythemia vera (PV). The treatment led to increased hepcidin levels, reduced serum iron, and decreased phlebotomy needs. The results indicate a potential breakthrough in managing PV symptoms and controlling hematocrit levels.
Read more →IRONDisc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine, Inc. will participate in several upcoming investor conferences, including the Cantor Fitzgerald Global Healthcare Conference and the Wells Fargo 21st Annual Healthcare Conference. The management team will engage in fireside chats, providing insights into the company's focus on novel treatments for hematologic diseases. Live webcasts will be available for those unable to attend in person.
Read more →IRONDisc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Disc Medicine, Inc. announced multiple presentations at the SOHO Annual Meeting, including initial data from the Phase 2 RESTORE-PV trial of DISC-3405 for polycythemia vera. The presentations will showcase safety and efficacy data from the trial, emphasizing the company's ongoing commitment to developing treatments for hematologic diseases. The meeting will take place in Houston from September 9-12, 2026.
Read more →IRON▲ +7.5%on this news
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
Disc Medicine reported its financial results for Q2 2026, highlighting significant advancements in its clinical programs. The company completed a Type A meeting with the FDA regarding bitopertin, with topline data from the Phase 3 APOLLO study expected in Q4 2026. Additionally, the RESTORE-PV Phase 2 study is fully enrolled, and initial data is anticipated in Q3 2026. Disc maintains a strong financial position with substantial cash reserves.
Read more →IRONDisc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
Disc Medicine presented positive clinical updates at the EHA Annual Meeting, showcasing significant results from the RALLY-MF trial for DISC-0974 in myelofibrosis patients and the HELIOS trial for bitopertin in erythropoietic protoporphyria. The data indicate durable anemia responses and improved light tolerance, respectively. The company anticipates further developments in its clinical programs, including upcoming discussions with the FDA.
Read more →IRONDisc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
Disc Medicine has completed a Type A meeting with the FDA regarding the Complete Response Letter for bitopertin, a treatment for erythropoietic protoporphyria. The FDA indicated that the ongoing Phase 3 APOLLO study could support a response to the CRL and potential traditional approval. Results from the APOLLO study are anticipated in Q4 2026, with a CRL response submission planned by the end of 2026.
Read more →IRON▼ -5.5%on this news
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Disc Medicine presented updated positive data from the RALLY-MF Phase 2 trial at the ASCO Annual Meeting. The trial demonstrated significant anemia responses in patients with myelofibrosis, showing improvements regardless of transfusion status or JAK inhibitor therapy. The investigational drug DISC-0974 was well-tolerated, with promising results in hemoglobin increases and transfusion independence.
Read more →IRONDisc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
Disc Medicine has announced an expanded access program for bitopertin, aimed at patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). This program allows eligible patients to access the treatment prior to regulatory approval. Bitopertin is currently being evaluated in the Phase 3 APOLLO clinical trial, with results expected in Q4 2026 and a potential FDA decision by mid-2027.
Read more →IRONDisc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
Read more →IRONDisc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
Disc Medicine reported its first quarter 2026 financial results, highlighting the completion of enrollment in the Phase 3 APOLLO study of bitopertin for erythropoietic protoporphyria, with topline data expected in Q4 2026. The company also announced updates on its other clinical programs, including DISC-0974 and DISC-3405, with significant financial resources to support ongoing operations. Despite a net loss increase, the company remains optimistic about its pipeline and future milestones.
Read more →IRONDisc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
Disc Medicine announced an oral presentation of data from the RALLY-MF Phase 2 trial of DISC-0974, targeting anemia in myelofibrosis. The presentation will occur at the ASCO Annual Meeting from May 29 to June 2, 2026. Initial results indicate unprecedented anemia response rates, showcasing the drug's potential in treating this difficult condition.
Read more →IRONDisc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
Disc Medicine has completed enrollment for the Phase 3 APOLLO trial of bitopertin, now involving 183 participants due to high demand. The trial aims to evaluate bitopertin's effectiveness in treating erythropoietic protoporphyria (EPP). Results are expected in Q4 2026, with a potential FDA decision by mid-2027.
Read more →IRONDisc Medicine, Inc. Investigated by the Portnoy Law Firm
Disc Medicine, Inc. is under investigation by the Portnoy Law Firm for possible securities fraud following a significant drop in stock price. The decline of 21.91% occurred after the FDA issued a Complete Response Letter regarding their drug bitopertin, indicating regulatory issues with clinical trial data. Ongoing concerns about the drug's safety and efficacy have further weakened investor confidence. The law firm aims to assist investors in pursuing claims to recover losses incurred due to these developments.
Read more →IRONDisc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Disc Medicine, Inc. reported its financial results for Q4 and full year 2025, highlighting progress in its clinical programs. The company expressed confidence in the bitopertin program and the Phase 3 APOLLO study, aiming for FDA approval. Additionally, promising data from DISC-0974 and upcoming results from DISC-3405 were noted, indicating a strong pipeline.
Read more →IRON▲ +17.2%on this news
Bitopertin Regulatory Update February 2026 Disclaimer and FLS This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, b
Disc has received a Complete Response Letter from the FDA for bitopertin, particularly related to the adequacy of protoporphyrin IX as a biomarker. The FDA has requested further evidence from the ongoing APOLLO study to establish clinical efficacy. While Disc is determined to gather necessary data and respond to the agency's concerns, the response indicates significant hurdles ahead for regulatory approval. The completion of the APOLLO study is pivotal, with results expected in late 2026.
Read more →IRON▼ -21.9%on this newsshared move
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
Disc Medicine, Inc. announced the receipt of a Complete Response Letter from the FDA regarding its New Drug Application for bitopertin, intended for treating erythropoietic protoporphyria. While the FDA acknowledged supportive evidence from earlier trials, it highlighted the need for results from the ongoing Phase 3 APOLLO study before making a final decision. Enrollment for the APOLLO trial has been completed ahead of schedule, with topline data expected in Q4 2026.
Read more →IRONDisc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
Disc Medicine, Inc. has outlined its strategic priorities and achievements for 2026, highlighting significant progress in its clinical pipeline. The company received CNPV designation for bitopertin and submitted an NDA for accelerated FDA review. Positive Phase 2 data from DISC-0974 and the advancement of DISC-3405 into proof-of-concept studies were also noted. The company aims for a successful US launch of bitopertin while continuing to expand its clinical studies.
Read more →About Disc Medicine, Inc.
Headquarters321 ARSENAL STREET, SUITE 101, WATERTOWN, MA, 02472
BIOPHARMAWATCH ELITE PLUS
Trade the next IRON catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime